目的 觀察參脈注射液聯(lián)合左卡尼汀治療急性冠脈綜合征心律失常的臨床療效。方法 選取2015年1月-2017年5月如皋市人民醫(yī)院收治的急性冠脈綜合征繼發(fā)室性心律失?；颊?0例，隨機(jī)分為對(duì)照組和治療組，每組各45例。對(duì)照組靜脈滴注左卡尼汀注射液，3 g/次，1次/d；治療組在對(duì)照組的基礎(chǔ)上靜脈滴注參麥注射液，2 mL/次，1次/d。兩組患者均連續(xù)治療2周。評(píng)價(jià)兩組患者臨床療效，同時(shí)比較治療前后兩組患者心電圖檢測(cè)結(jié)果和血清指標(biāo)水平。結(jié)果 治療后，對(duì)照組和治療組臨床有效率分別為68.89%和93.33%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組室早數(shù)、短陣室速較治療前顯著減少，QTc間期顯著延長(zhǎng)，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組室早數(shù)、短陣室速明顯少于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清CD40配體（CD40L）、白介素-1β（IL-1β）、腫瘤壞死因子-α（TNF-α）水平均較治療前顯著降低（P<0.05）；且治療后治療組CD40L、IL-1β和TNF-α水平顯著低于對(duì)照組（P<0.05）。結(jié)論 參脈注射液聯(lián)合左卡尼汀治療急性冠脈綜合征室性心律失常臨床療效顯著，可有效地降低炎癥細(xì)胞因子水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical curative effect of Shenmai Injection combined with levocarnitine in treatment of ventricular arrhythmia of acute coronary syndrome. Methods Patients (90 cases) with ventricular arrhythmia of acute coronary syndrome in Rugao People's Hospital from January 2015 to May 2017 were randomly divided into control and treatment groups, and each group had 45 cases. Patients in the control group were iv administered with Levocarnitine Injection, 3 g/time, once daily. Patients in the treatment group were iv administered with Shenmai Injection on the basis of the control group, 2 mL/time, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, the ECG results and the serum index levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 68.89% and 93.33% respectively, and there were differences between two groups (P<0.05). After treatment, the ventricular arrhythmias and nonsustained ventricular tachycardia in two groups were significantly decreased, and QTc interval was significantly prolonged, and the difference was statistically significant in the same group (P<0.05). And the ventricular arrhythmias and nonsustained ventricular tachycardia in the treatment group after treatment were significantly less than those in the control group, with significant difference between two groups (P<0.05). After treatment, the serum CD40L, IL-1β, and TNF-α levels in two groups were significantly decreased (P<0.05), and these serum indexes levels in the treatment group after treatment were significantly lower than those in the control group (P<0.05). Conclusion Shenmai Injection combined with levocarnitine has good effect in treatment of ventricular arrhythmia of acute coronary syndrome, and can decrease inflammatory cytokine levels, which has a certain clinical application value.